Application of exosome blocker in treatment of sleep disorder
By using miR-24 blockers such as GW4869 to inhibit the production or secretion of miR-24, the shortcomings of traditional methods for treating sleep disorders have been overcome, enabling safe and effective improvement of hypoxia-induced sleep disorders and providing a new treatment strategy.
Patent Information
- Application Number
- CN202511656574.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-11-12
- Publication Date
- 2026-02-06
AI Technical Summary
Traditional treatments for sleep disorders suffer from drug dependence, significant side effects, short-lived efficacy, and inability to fundamentally address nerve damage. There is an urgent need to develop new treatment options that are safe and free of toxic side effects.
miR-24 blockers, including substances that inhibit the production, secretion, maturation, or interaction of miR-24 with target cells, such as GW4869, are used to prepare drugs for treating hypoxia-induced sleep disorders. The expression or activity of the miR-24 gene or protein is detected by screening methods to select candidate drugs.
Inhibiting miR-24 secretion significantly improved the reduction in total sleep and daytime sleep duration and sleep fragmentation induced by hypoxia stress, providing a new intervention strategy with broad application prospects.